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Introduction: The risk of symptomatic deep vein thrombosis
(DVT) among patients with non-small cell lung cancer (NSCLC)
has not been well studied. We conducted a retrospective cohort
study of patients with NSCLC to determine the incidence of DVT
and to characterize predictors of DVT in patients with NSCLC.
Methods: The pulmonary oncology database of the Sir Mortimer B.
Davis–Jewish General Hospital contains prospectively collected
clinical data on lung cancer patients since January 1, 1997. We
identified all consecutive patients with histologically confirmed new
diagnoses of NSCLC between January 1, 1997 and December 31,
2004, and we determined the occurrence of an objectively defined
DVT. Data on clinical and tumor characteristics were collected and
compared among patients with DVT and patients without DVT.
Results: Of the 493 NSCLC patients included in the cohort for a
total of 634 person-years, 67 (13.6%) patients developed objectively
confirmed DVTs, with an incidence of 110 cases (95% confidence
interval [CI] 80, 130) per 1000 person-years. An adjusted multiva-
riable regression analysis showed that advanced stage (rate ratio
[RR] 2.63, 95% CI 1.38, 5.00) and male sex (RR 1.75, 95% CI
1.03–2.94) were independent predictors of DVT.
Conclusions: Our results show a high incidence of DVT in NSCLC
patients. Advanced stage and, to a lesser extent, male sex, are
important predictors of DVT. Trials to evaluate the use of prophy-
lactic anticoagulant treatments in patients with NSCLC should be
conducted.
Key Words: Non-small cell lung cancer, Deep vein thrombosis,
Risk.
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Deep vein thrombosis (DVT) is a well-recognized com-plication of cancer and is estimated to occur in 4% to
17% of patients with underlying malignancies.1–4 It is an
important health problem in cancer patients and is associated
with significant morbidity and mortality. Specifically, cancer
patients with thrombosis have a four- to sixfold higher risk of
dying after an acute thrombotic event than do patients without
cancer.5 Furthermore, patients with cancer and thrombosis
have a two- to threefold lower survival rate than those with
cancer and without thrombosis.6 It is believed that the com-
plications of venous thrombosis, such as recurrent thrombosis
or fatal pulmonary embolism, do not entirely explain the
decreased survival rate, and that perhaps the tumors of pa-
tients with thrombosis are more aggressive than those of
patients without thrombosis.
Among patients with malignancies presenting with
DVT, lung, prostate, breast, and colorectal cancer are the
most commonly identified; collectively, they comprise ap-
proximately 10% to 15% of the DVT patient population.7 As
such, it is commonly believed that patients with these cancer
types are at a very high risk of DVT. Nevertheless, these
associations are largely derived from clinical trials evaluating
antithrombotic agents in which approximately 20% of sub-
jects have had an underlying malignancy and from autopsy
studies in which mucin-producing adenocarcinomas, such as
those of lung and colorectal origin, have been shown to be
highly associated with venous thrombosis. In fact, few data
exist regarding the incidence of symptomatic DVT in patients
with these cancers, and there are even fewer reports in
patients with lung cancer.
Because lung cancer, specifically non-small cell lung
cancer (NSCLC), which constitutes 85% of all lung cancers,8
is a major public health problem associated with a high
incidence and case-fatality rate, specific and accurate esti-
mates of DVT frequency are important in the care of these
patients. To study the association between DVT and NSCLC,
we investigated the risk of DVT in a well-defined cohort of
patients with NSCLC, and we assessed clinical characteristics
to identify those patients at high risk for DVT.
METHODS
Patient Population
We retrospectively assembled a cohort of patients with
NSCLC who were registered in the pulmonary oncology
database of the Sir Mortimer B. Davis (SMBD)–Jewish
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General Hospital, a tertiary care hospital, between January
1997 and December 2004. The database contains prospec-
tively collected information on all consecutive patients with
lung cancer referred to the pulmonary oncology clinic since
January 1997. It includes demographic and clinical informa-
tion and is maintained by specialized oncology data managers
and research assistants. It has been used by other researchers,
including members of our research team, to answer clinical
research questions.9,10
Patients were eligible to enter the cohort if they had a
first diagnosis of histologically confirmed NSCLC and did
not have a concurrent diagnosis of DVT at the time of the
lung cancer diagnosis. Patients were excluded if they only
briefly visited the SMBD–Jewish General Hospital pulmo-
nary oncology clinic for diagnosis or therapy with no long-
term follow-up, or if they had no recorded information.
Patients exited the cohort on the earliest of the following
dates: (1) at the end of the study period (December 31, 2004),
(2) on the date of diagnosis of DVT, or (3) at the time of
death.
DVT Diagnosis
We ascertained the occurrence of symptomatic DVT
since diagnosis of NSCLC from the database, the patient’s
medical record, and the records of the vascular laboratory of
the SMBD–Jewish General Hospital. The vascular laboratory
receives and registers inpatient and outpatient requests for
duplex venous ultrasonography and archives all duplex ultra-
sound reports that confirm a venous thrombosis. As a result,
DVT occurrences that were ascertained from the database or
from a patient’s medical record were then confirmed with the
vascular laboratory records. The patient’s unique hospital
number was used to link the database to the vascular labora-
tory. The following thrombotic events were excluded from
the analysis: (1) thrombotic episodes identified in the data-
base or in patient medical records that could not be confirmed
by the vascular laboratory, and (2) a duplex ultrasound report
indicating a superficial thrombophlebitis or chronic venous
changes. Confirmation of an acute DVT by venous duplex
ultrasonography was based on noncompressibility of the
thrombosed vein with reduced or absent blood flow or direct
visualization of a hyperechoic intraluminal thrombus. Each
DVT was characterized with regard to its anatomic location
(upper versus lower extremity) and, in the case of a lower-
extremity DVT, proximal (popliteal–femor–iliac) versus dis-
tal (collecting calf veins) DVT.
Data Collection
From the database, we recorded (1) demographic data:
date of birth, age at NSCLC diagnosis, and sex; (2) tumor
characteristics: histologic classification and stage of tumor;
and (3) clinical characteristics: Eastern Cooperative Oncol-
ogy Group (ECOG) performance status at time of NSCLC
diagnosis, and chemotherapy and surgery received. Informa-
tion on the date of diagnosis and anatomic location of the
DVT was retrieved from the vascular laboratory records.
Information on the date of death was retrieved from the
database and patient medical records.
Statistical Analysis
Data were analyzed using SAS/STAT software, version
8.2 for Windows. For each patient, person-years of follow-up
were counted from the date of lung cancer diagnosis until the
date of the DVT, the date of death, or the end of the study
period. By dividing the number of cases of DVT by the
number of person-years, we computed the incidence rate of
DVT. Simple descriptive statistics (means with standard
deviation; proportions) were used to summarize demo-
graphic, clinical, and tumor characteristics of the cohort.
Comparisons between patients with DVT and those without
DVT were made using Fisher’s exact test, Student’s t test, or
2 test, as appropriate. A two-sided p value 0.05 was
considered statistically significant.
To assess which characteristics predicted the occur-
rence of DVT, eight variables (age dichotomized at 65 years
of age, sex, ECOG performance, tumor type, clinical stage,
chemotherapy, surgery) were assessed using Poisson regres-
sion modeling.11 After assessing for collinearity among the
variables (correlation coefficient 0.6 indicated an important
correlation) and statistically significant interactions between
the variables (Breslow–Day test for homogeneity), predictors
identified in the univariate analysis were included in different
models and compared to determine confounders, and the
Akaike information criterion was used to select the best
model to explain the risk of DVT. All p values were deter-
mined using two-tailed tests of significance, and 95% confi-
dence intervals (CI) are provided.
Ethical Issues and Confidentiality
The study protocol was approved by the review ethics
committee of the SMBD–Jewish General Hospital. Because
the study used data maintained by the pulmonary oncology
division, no individual consent was obtained. Only data
relevant to the study was provided for analyses.
RESULTS
From January 1997 to December 2004, 493 patients
with NSCLC were included in the study. We excluded 40
patients because they briefly attended the clinic for diagnosis
or therapy, four patients because a primary diagnosis of lung
cancer could not be histologically confirmed, and six patients
because of non–lung cancer metastases. Among the 493
patients, a total 634 person-years were accrued and 67 DVT
episodes were confirmed. The incidence density of DVT was
110 (95% CI  80, 130) per 1000 person-years. The overall
incidence of DVT was 13.6%, with 64% of patients devel-
oping the DVT within 6 months of diagnosis. All DVT
episodes occurred in the lower extremity, with 32 (47.8%)
episodes limited to the distal leg veins and 35 (52.2%)
involving the proximal leg veins.
Table 1 presents the characteristics of the study popu-
lation. Overall, 60% were male, and the mean age at cancer
diagnosis was 65 years. Approximately 60% of the tumors
were adenocarcinoma, and 25% were of squamous-cell ori-
gin. At the time of diagnosis, 72% of patients had stage IIIb
or greater disease. In all, 246 (49.9%) study patients received
chemotherapy. None of the patients received a vascular
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endothelial growth factor inhibitor, which, in combination
with chemotherapy, is associated with an increased risk of
thrombosis.12
Table 2 compares clinical and tumor characteristic in
patients with and without DVT. Advanced cancer stage
(IIIb) was more frequent in patients with DVT compared
with patients without DVT. This difference was statistically
significant. Distribution of other characteristics was similar
between the two groups. Of the 31 patients who received
chemotherapy before a diagnosis of DVT, 17 (54.8%) pa-
tients developed the DVT during a course of chemotherapy,
and 14 (45.2%) patients were diagnosed, on average, 4.1
months after completion of chemotherapy. Eight of the 67
DVT events (11.9%) were observed in patients who had had
surgical procedures, with a median time to DVT of 4.2
months.
The best-fit multivariate model, using the eight charac-
teristics examined as potential predictors of DVT in the
univariate analysis (Table 3), showed that stage (IIIb versus
IIIb; adjusted rate ratio [RR] 2.63; 95% CI [1.38, 5.00]) and
sex (male versus female; adjusted RR 1.75, 95% CI [1.03,
2.94]) were important predictors of DVT in this study pop-
ulation (Table 3). Although lung or brain surgery was iden-
tified as potentially protective against DVT development in
the univariate analysis, it was found to be a confounder of the
association between clinical stage and DVT development
(Table 3) because it was highly associated with clinical stage.
Specifically, the risk of having lung or brain surgery in
patients with stage I, II, or IIIa NSCLC was almost fivefold
higher than that for patients with NSCLC of stage IIIb or
higher (RR 4.84, 95% CI [3.10,7.54]).
DISCUSSION
The risk of DVT in this large-cohort study of 493
patients with NSCLC was high, with an estimated incidence
of 110 per 1000 patient-years, which is 100-fold higher than
the thrombosis risk in the general population (1–2 per 1000
patient-years).13 Patients with lung cancer have always been
assumed to be at a high risk of venous thrombosis, mostly
because numerous antithrombotic trials and cohort studies of
patients with venous thrombosis have demonstrated that lung
cancer is common in these patients.14,15 Nevertheless, few
studies have reported on the actual incidence or absolute risk
of venous thrombosis in cancer patients, and, to our knowl-
edge, only six previous studies have described the risk of
venous thrombosis in patients with lung cancer.
In the earliest such study, Ziomek and colleagues16
performed serial venous duplex scanning on 77 patients
undergoing thoracotomy, of whom 50 patients (65%) had
NSCLC; they report an overall incidence of venous throm-
bosis (including pulmonary embolism) of 26% and a DVT
incidence (including distal DVT) of 19.5% in the 30-day
TABLE 1. Characteristics of Study Cohort
Number Proportion
Characteristic (n  493) (%)
Age (mean) 64.5 —
Sex (male) 297 60.24
NSCLC type
Adenocarcinoma 294 59.6
Squamous cell 122 24.8
Othera 77 15.6
Stage of NSCLC
IIIb 355 72.0
IIIb 138 28.0
ECOG performance status
0 or 1 389 78.9
2–4 355 21.1
Chemotherapy
No 247 50.1
Yes 246 49.9
Surgery
No 409 83.0
Lung or brainb 72 14.6
Other 12 2.4
Deep vein thrombosis
No 426 86.4
Yes 67 13.6
Distal leg only 32
Proximal leg 35
NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group.
a Include poorly or undifferentiated NSCLC, adenosquamous, and undifferentiated
large-cell carcinoma.
b Includes mediastinotomy and ventriculoperitoneal shunt.
TABLE 2. Comparison of Clinical Characteristics in Patients
with and without Deep Vein Thrombosis (DVT)
Patients with Patients without
Characteristic DVT (n  67) DVT (n  426) p
Mean age (yr) 60.3 63.7 0.16a
Sex (%)
Male 46 (69) 251 (59) 0.13
Female 21 (31) 175 (41)
NSCLC type (%)
Squamous cell (reference) 17 (25) 105 (25)
Adenocarcinoma 40 (60) 254 (60) 0.99
Other 10 (15) 67 (15) 0.87
Clinical stage (%)
IIIb 55 (82.1) 300 (70.4) 0.05
IIIb 12 (17.9) 126 (29.6)
ECOG performance status (%)
0 or 1 53 (79.1) 336 (78.9) 0.97
2–4 14 (20.9) 90 (21.1)
Chemotherapy (%)
No 36 (54) 211 (49.5) 0.52
Yes 31 (46) 215 (50.5)
Surgery (%)
No (reference) 59 (88.1) 350 (82.2)
Lung or brain 6 (9.0) 66 (15.5) 0.16
Other 2 (3.0) 10 (2.3) 0.67b
NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group.
a Student’s t test.
b Fisher’s exact test.
Others: 2 test.
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postoperative period. Unlike our study, this was an entirely
surgical cohort, and thrombotic events included asymptom-
atic DVT. This may explain the higher incidence of DVT
compared with that observed in our study.
In a more recent Medicare database study of more than
1 million cancer patients hospitalized during 1988 to 1990, 61
venous thrombosis events, which included pulmonary embo-
lism, were observed per 10,000 lung cancer patients during
183 days of follow-up, for a calculated annual incidence of
12.2 per 1000 person-years.3 Unlike our study, thrombotic
events were not objectively defined; instead, they were iden-
tified by discharge diagnoses, which may not accurately
reflect events that occurred during hospitalization. Moreover,
Medicare data have been shown to underreport hospitaliza-
tions by 10% to 27%.17 As a result, there may have been
incomplete ascertainment of thrombosis events, which may
explain the much lower incidence in this study compared with
our observed rate.
In their prospective cohort of 537 patients with
NSCLC, Blom and colleagues18 observed 39 venous throm-
bosis events, including pulmonary embolism, in 879 years of
follow-up, for an overall incidence of venous thrombosis of
44 cases per 1000 patient-years. Once again, the lower
incidence in comparison with our reported incidence of 110
per 1000 patient-years may be explained in part by the
difference in verification of venous thrombosis. Unlike our
study, thrombotic episodes were not objectively verified;
instead, they were ascertained either by reviewing medical
records of hospitals and anticoagulation clinics or by consult-
ing the general practitioner. Blom and colleagues19 also have
described the incidence of venous thrombosis among patients
with cancer, using linked records of a cancer registry and an
anticoagulation clinic database in the Netherlands; they report
an incidence of 27.6 per 1000 patient-years among the 9336
patients with lung cancer. Nevertheless, as described by the
authors, there were several limitations to the study, including
the fact that incident cases of venous thrombosis were not
completely captured because the indication for anticoagula-
tion was not always registered by the clinics, and further-
more, patients diagnosed with venous thrombosis may not
have been referred to the anticoagulation clinics for treat-
ment. For example, because of the limited performance of
compression ultrasound to diagnose distal DVT and the
relatively low risk of proximal extension and embolization of
isolated distal DVT, several diagnostic centers do not sys-
tematically screen the calf veins of patients referred for DVT
investigation, and in centers where isolated distal DVT is
diagnosed, it may not always be treated.20 Hence, the inclu-
sion of distal DVT episodes in our study may account for the
higher DVT incidence compared with that reported in the
literature. Although data from prospective cohort studies of
surgical and medical patients seem to suggest that the rate of
proximal extension and embolization of isolated distal DVT
is low (anywhere between 0.9% and 5.7%20), the clinical
significance of distal DVT in cancer patients has not been
well studied.
Finally, Numico and colleagues21 prospectively ob-
served 108 patients with stage III or IV NSCLC for an
average period of 8.7 months, recording a total of 22 symp-
tomatic vascular events among 19 patients (17.6%, 95% CI
[10.3, 24.8%]). Twelve of these events were venous throm-
botic episodes (including pulmonary embolism) among 12
patients, for a calculated cumulative risk of 11%. Similarly,
in a post hoc analysis using data from two phase III trials of
prinomastat (matrix metalloproteinase inhibitor) versus pla-
cebo with concomitant chemotherapy in patients with ad-
vanced NSCLC (stage IIIb or IV), an overall venous throm-
bosis incidence of 92.8 (95% CI [66.8, 118.7]) per 1000
patient-years was observed, with a “background” (patient-
years without prinomastat or central venous catheter) inci-
dence of 68 (95% CI [45.24, 90.8]) per 1000 patient-years.22
In both studies, a relatively high risk of thrombosis was
observed among patients with advanced-stage NSCLC. Our
study population largely comprised patients with advanced-
stage NSCLC (72% had stage IIIb or IV), and several studies
have shown a direct association between cancer stage and
thrombosis risk.1,23 Our data show that patients with stage
IIIb or IV NSCLC are, on average, 2.6 times more likely to
be diagnosed with DVT than are patients with less-advanced-
stage NSCLC. We hypothesize that patients with advanced
cancer are more hypercoagulable than patients with localized
cancer and are more likely to suffer complications, such as
immobility, that increase the risk of thrombosis.
TABLE 3. Predictors of Deep Vein Thrombosis in a Study
Population of 493 Patients
Rate Ratio Adjusted Rate Ratio
Characteristic
(95% Confidence
Interval)
(95% Confidence
Interval)
Age
65 years 0.86 (0.53, 1.40)
65 years —
Sex
Male (%) 1.72 (1.01, 2.94) 1.75 (1.03, 2.94)a
Female (%) — —
NSCLC type
Adenocarcinoma (%) 1.24 (0.69, 2.21)
Squamous cell (%) —
Other (%) 1.44 (0.66, 3.18)
Clinical stage
IIIb (%) 2.98 (1.59, 5.58) 2.63 (1.38, 5.00)a
IIIb (%) — —
ECOG performance status
0 or 1 (%) —
2–4 (%) 1.67 (0.91, 3.06)
Surgery
Lung or brain (%) 0.38 (0.16, 0.88) 0.52 (0.22, 1.24)a
Other (%) 1.04 (0.25, 4.24) 1.39 (0.34, 5.75)a
No (%) — —
Chemotherapy
Yes (%) 0.67 (0.41, 1.08)
No (%) —
NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group.
a Best model fit: log (rate)8.4854 0.5560 sex 0.9653 stage 0.6478
surgery of lung or brain  0.3292 other surgery.
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In addition to advanced stage, male sex independently
predicted the occurrence of DVT in our study population.
Although population-based prospective studies have shown
sex-related differences in the epidemiology of venous throm-
bosis—specifically, men have a 1.2- to 3.6-fold increased risk
of recurrence after an initial thrombosis episode24–26—there
have been no published studies in support of a higher risk
of DVT in men with cancer versus women with cancer.
Nevertheless, our results may have been confounded by
unmeasured risk factors for venous thrombosis that may be
more prevalent in men than in women. For example,
compared with women, men are more likely to be diag-
nosed with conditions such as cardiovascular disease;
hence, they are more likely to be hospitalized. This finding
also may have been spurious, because the lower limit of
the CI was close to unity.
We did not find an increased risk of DVT related to
surgery, likely because adequate prophylaxis was given to
patients who underwent surgery. Nonetheless, we cannot
exclude the possibility that the sample size may have been too
small to detect a clinically significant association. Also,
exposure to chemotherapy did not predict the occurrence of
DVT in our study. Nevertheless, we did not assess the risk of
DVT during the period of chemotherapy, which has been
reported in patients with lung, breast, and gynecological
cancer to be increased.19,27,28 Finally, upper-extremity DVT
events were not observed, likely because of the low preva-
lence of central venous catheter use in our study population.
Our study had important limitations. First, as a result of
its retrospective nature, our study lacked information on other
potentially important predictors of DVT, such as a past
history of venous thrombosis and use of anticoagulant med-
ications. Second, the number of DVT events may have been
underestimated because we could only detect patients with
symptomatic and objectively verified DVT, and we may have
missed patients who were treated for probable DVT without
performing objective testing or who were diagnosed with
DVT by other diagnostic modalities, such as nonduplex
compression ultrasound, venography, computed tomographic
angiography, and magnetic resonance imaging. Nevertheless,
this number is likely very small, because nonduplex compres-
sion ultrasound and venography are rarely performed in our
institution, and computed tomography angiography and mag-
netic resonance imaging specifically for the diagnosis of
venous thrombosis were not yet in use in our institution
during the study period. Finally, information on pulmonary
embolism was not reliably recorded in the pulmonary oncol-
ogy database, and linkage to nuclear medicine and radiology
departmental databases was not possible. As a result, we
could not report on the incidence of pulmonary embolism in
our cohort.
In conclusion, our study shows that the occurrence of
DVT in patients with NSCLC is more common than has been
reported previously. Moreover, like others, we have con-
firmed that advanced stage was a strong predictor of DVT.
Although anticoagulant, prophylactic therapies are well es-
tablished in patients with cancer, including lung cancer, who
are hospitalized and/or undergoing surgery,29 the findings
from this study support the rationale for an evaluation of
anticoagulant DVT prophylaxis beyond the postoperative
period and time of hospitalization. In particular, clinical trials
should be conducted to assess the efficacy and safety of
prophylactic anticoagulation in patients with NSCLC, partic-
ularly advanced-stage lung cancer. Also, the effects on mor-
tality and quality of life should be addressed, because the role
of low–molecular weight heparins in improving the survival
of cancer patients is being investigated continuously.30–32
Finally, prospective studies are needed to better evaluate the
effect of gender on the risk of DVT among patients with
NSCLC.
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